1
|
Bamou FZ, Le TM, Tayeb BA, Tahaei SAS, Minorics R, Zupkó I, Szakonyi Z. Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives. Chemistry 2022; 11:e202200169. [PMID: 36200514 PMCID: PMC9535514 DOI: 10.1002/open.202200169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2022] [Revised: 08/25/2022] [Indexed: 11/08/2022]
Abstract
A series of novel heterocyclic structures, namely 1,3‐oxazines, 1,3‐thiazines and 2,4‐diaminopyrimidines, were designed and synthesised. The bioassay tests demonstrated that, among these analogues, 2,4‐diaminopyridine derivatives showed significant antiproliferative activity against different human cancer cell lines (A2780, SiHa, HeLa, MCF‐7 and MDA‐MB‐231). Pyrimidines substituted with N2‐(p‐trifluoromethyl)aniline, in particular, displayed a potent inhibitory effect on the growth of cancer cells. Structure–activity relationships were also studied from the aspects of stereochemistry on the aminodiol moiety as well as exploring the effects of substituents on the pyrimidine scaffold.
Collapse
Affiliation(s)
- Fatima Z. Bamou
- Institute of Pharmaceutical Chemistry andMTA-SZTE Stereochemistry Research GroupHungarian Academy of SciencesUniversity of SzegedEötvös u. 66720SzegedHungary
| | - Tam M. Le
- Institute of Pharmaceutical Chemistry andMTA-SZTE Stereochemistry Research GroupHungarian Academy of SciencesUniversity of SzegedEötvös u. 66720SzegedHungary
| | - Bizhar A. Tayeb
- Department of Pharmacodynamics and BiopharmacyUniversity of SzegedEötvös u. 66720SzegedHungary
| | - Seyyed A. S. Tahaei
- Department of Pharmacodynamics and BiopharmacyUniversity of SzegedEötvös u. 66720SzegedHungary
| | - Renáta Minorics
- Department of Pharmacodynamics and BiopharmacyUniversity of SzegedEötvös u. 66720SzegedHungary
| | - István Zupkó
- Department of Pharmacodynamics and BiopharmacyUniversity of SzegedEötvös u. 66720SzegedHungary
| | - Zsolt Szakonyi
- Institute of Pharmaceutical Chemistry andMTA-SZTE Stereochemistry Research GroupHungarian Academy of SciencesUniversity of SzegedEötvös u. 66720SzegedHungary
| |
Collapse
|
2
|
Li Q, Chen L, Jian XE, Lv DX, You WW, Zhao PL. Design, synthesis and antiproliferative activity of novel 2,4-diamino-5-methyleneaminopyrimidine derivatives as potential anticancer agents. Bioorg Med Chem Lett 2021; 47:128213. [PMID: 34157389 DOI: 10.1016/j.bmcl.2021.128213] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 06/14/2021] [Accepted: 06/16/2021] [Indexed: 01/07/2023]
Abstract
In order to discover new anticancer agents, 25 novel 2,4-diamino-5-methyleneaminopyrimidine derivatives were designed and synthesized based on our previous work via a ring-opening strategy. Among them, compared with 5-FU, compound 7i exhibited 4.9-, 2.9-, 2.1-, and 3.0-fold improvement in inhibiting HCT116, HT-29, MCF-7, and HeLa cells proliferation with IC50 values of 4.93, 5.57, 8.84, and 14.16 μM, respectively. Moreover, further mechanistic studies indicated that compound 7i could concentration-dependently induce cell cycle arrest and apoptosis in HCT116 cells. These findings revealed that 2,4-diamino-5-methyleneaminopyrimidine scaffold has potential for further investigation to explore novel anticancer agents.
Collapse
Affiliation(s)
- Qiu Li
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China
| | - Lin Chen
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China
| | - Xie-Er Jian
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China
| | - Dong-Xin Lv
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China
| | - Wen-Wei You
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China
| | - Pei-Liang Zhao
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China.
| |
Collapse
|
3
|
Campestre C, Keglevich G, Kóti J, Scotti L, Gasbarri C, Angelini G. Microwave-assisted simple synthesis of 2-anilinopyrimidines by the reaction of 2-chloro-4,6-dimethylpyrimidine with aniline derivatives. RSC Adv 2020; 10:12249-12254. [PMID: 35497585 PMCID: PMC9050660 DOI: 10.1039/d0ra00833h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 03/18/2020] [Indexed: 02/05/2023] Open
Abstract
A series of 2-anilinopyrimidines including novel derivatives has been obtained from 2-chloro-4,6-dimethylpyrimidine by aromatic nucleophilic substitution with differently substituted anilines under microwave conditions. The substituents had a significant impact on the course and efficiency of the reaction. The results reported herein demonstrate the efficacy of microwaves in the synthesis of the title heterocyclic compounds as compared to the results obtained with conventional heating. The 2-anilinopyrimidines described are of potential bioactivity. A rapid, one pot, green approach by microwave heating in ethanol provides a new method to obtain active and new potentially active compounds in high yields.![]()
Collapse
Affiliation(s)
- Cristina Campestre
- Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara via dei Vestini 66100 Chieti Italy +39-0871-3554785
| | - György Keglevich
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics 1521 Budapest Hungary
| | - János Kóti
- Spectroscopic Research Division, Gedeon Richter Plc. 1475 Budapest Hungary
| | - Luca Scotti
- Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" of Chieti-Pescara via dei Vestini 66100 Chieti Italy
| | - Carla Gasbarri
- Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara via dei Vestini 66100 Chieti Italy +39-0871-3554785
| | - Guido Angelini
- Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara via dei Vestini 66100 Chieti Italy +39-0871-3554785
| |
Collapse
|
4
|
Nucleophilic Arylation of Halopurines Facilitated by Brønsted Acid in Fluoroalcohol. MOLECULES (BASEL, SWITZERLAND) 2019; 24:molecules24213812. [PMID: 31652675 PMCID: PMC6865213 DOI: 10.3390/molecules24213812] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 10/18/2019] [Accepted: 10/21/2019] [Indexed: 12/01/2022]
Abstract
Various aryl-substituted purine derivatives were synthesized through the direct arylation of halopurines with aromatic compounds, facilitated by the combination of triflic acid and fluoroalcohol. This metal-free method is complementary to conventional coupling reactions using metal catalysts and reagents for the syntheses of aryl-substituted purine analogues.
Collapse
|
5
|
Synthesis and anticancer activity evaluation of novel azacalix[2]arene[2]pyrimidines. Eur J Med Chem 2018; 151:214-225. [DOI: 10.1016/j.ejmech.2018.02.079] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Revised: 02/23/2018] [Accepted: 02/25/2018] [Indexed: 12/22/2022]
|
6
|
Parveen I, Ahmed N, Idrees D, Khan P, Hassan MI. Synthesis, estrogen receptor binding affinity and molecular docking of pyrimidine-piperazine-chromene and -quinoline conjugates. Bioorg Med Chem Lett 2017; 27:4493-4499. [DOI: 10.1016/j.bmcl.2017.07.077] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Revised: 07/22/2017] [Accepted: 07/28/2017] [Indexed: 10/19/2022]
|
7
|
Coxon C, Anscombe E, Harnor SJ, Martin MP, Carbain B, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble MEM, Sivaprakasam M, Tudhope SJ, Turner DM, Wang LZ, Wedge SR, Wong C, Griffin RJ, Endicott JA, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem 2017; 60:1746-1767. [PMID: 28005359 PMCID: PMC6111440 DOI: 10.1021/acs.jmedchem.6b01254] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Indexed: 02/08/2023]
Abstract
Purines and related heterocycles substituted at C-2 with 4'-sulfamoylanilino and at C-6 with a variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1. 6-Substituents that favor competitive inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1. Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) that exhibited high potency toward CDK2 (IC50 0.044 μM) but was ∼2000-fold less active toward CDK1 (IC50 86 μM). This compound is therefore a useful tool for studies of cell cycle regulation. Crystal structures of inhibitor-kinase complexes showed that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket and that is preferred in CDK2 but has not been observed in CDK1. This aspect of the active site may be exploited for the design of inhibitors that distinguish between CDK1 and CDK2.
Collapse
Affiliation(s)
- Christopher
R. Coxon
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Elizabeth Anscombe
- Department
of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, U.K.
| | - Suzannah J. Harnor
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Mathew P. Martin
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - Benoit Carbain
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Bernard T. Golding
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Ian R. Hardcastle
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Lisa K. Harlow
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Svitlana Korolchuk
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - Christopher J. Matheson
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - David R. Newell
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - Martin E. M. Noble
- Department
of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, U.K.
| | - Mangaleswaran Sivaprakasam
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Susan J. Tudhope
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - David M. Turner
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Lan Z. Wang
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - Stephen R. Wedge
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, Newcastle University Medical School, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, U.K.
| | - Christopher Wong
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Roger J. Griffin
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| | - Jane A. Endicott
- Department
of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, U.K.
| | - Céline Cano
- Newcastle
Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle
upon Tyne NE1 7RU, U.K.
| |
Collapse
|
8
|
Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Med Chem 2016; 8:2047-2076. [DOI: 10.4155/fmc-2016-0129] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Deregulation of the cell cycle is a common feature in human cancer. The inhibition of cyclin-dependent kinases (CDKs), which play a crucial role in control of the cell cycle, has always been one of the most promising areas in cancer chemotherapy. This review first summarizes the biology of CDKs and then focuses on the recent advances in both broad-range and selective CDK inhibitors during the last 5 years. The design rationale, structural optimization and structure–activity relationships analysis of these small molecules have been discussed in detail and the key interactions with the amino-acid residues of the most important compounds are highlighted. Future perspectives for CDKs inhibitors will be defined in the development of highly selective CDK inhibitors, an accurate knowledge of gene control mechanism and further predictive biomarker research.
Collapse
|
9
|
Beale G, Haagensen EJ, Thomas HD, Wang LZ, Revill CH, Payne SL, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer 2016; 115:682-90. [PMID: 27529512 PMCID: PMC5023777 DOI: 10.1038/bjc.2016.238] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 05/31/2016] [Accepted: 07/14/2016] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clinical trials. Similarly, CDKs have been investigated as cancer drug targets. METHODS We have synthesised and characterised a series of 6-aminopyrimidines identified from a kinase screen that inhibit PI3K and/or mTOR and/or CDK2. Kinase inhibition, tumour cell growth, cell cycle distribution, cytotoxicity and signalling experiments were undertaken in HCT116 and HT29 colorectal cancer cell lines, and in vivo HT29 efficacy studies. RESULTS 2,6-Diaminopyrimidines with an O(4)-cyclohexylmethyl substituent and a C-5-nitroso or cyano group (1,2,5) induced cell cycle phase alterations and were growth inhibitory (GI50<20 μM). Compound 1, but not 2 or 5, potently inhibits CDK2 (IC50=0.1 nM) as well as PI3K, and was cytotoxic at growth inhibitory concentrations. Consistent with kinase inhibition data, compound 1 reduced phospho-Rb and phospho-rS6 at GI50 concentrations. Combination of NU6102 (CDK2 inhibitor) and pictilisib (GDC-0941; pan-PI3K inhibitor) resulted in synergistic growth inhibition, and enhanced cytotoxicity in HT29 cells in vitro and HT29 tumour growth inhibition in vivo. CONCLUSIONS These studies identified a novel series of mixed CDK2/PI3K inhibitors and demonstrate that dual targeting of CDK2 and PI3K can result in enhanced antitumour activity.
Collapse
Affiliation(s)
- Gary Beale
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK
| | - Emma J Haagensen
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK
| | - Huw D Thomas
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK
| | - Lan-Zhen Wang
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK
| | - Charlotte H Revill
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| | - Sara L Payne
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| | - Bernard T Golding
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| | - Ian R Hardcastle
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| | - David R Newell
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK
| | - Roger J Griffin
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| | - Celine Cano
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Bedson Building, Newcastle NE1 7RU, UK
| |
Collapse
|
10
|
Cortese D, Chegaev K, Guglielmo S, Wang LZ, Golding BT, Cano C, Fruttero R. Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. ChemMedChem 2016; 11:1705-8. [PMID: 27355194 DOI: 10.1002/cmdc.201600108] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 06/07/2016] [Indexed: 11/09/2022]
Abstract
The potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor NU6027 (6-cyclohexylmethoxy-5-nitroso-2,4-diaminopyrimidine) was used as the lead for the synthesis of a series of analogues in order to provide further insight into the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors. Aliphatic amino substituents were introduced at position 2. The use of linear or less sterically hindered amines gave rise to compounds endowed with slightly better activity than the lead; on the other hand, the compounds were less active if a bulkier amino substituent was used. Substitution of the 5-nitroso group with a 5-cyano-NNO-azoxy moiety afforded a new class of inhibitors, the activity of which against CDK2 was found to be similar to that of the nitroso series. The most active nitroso compound was 8 b ((2S)-2-[(4-amino-6-cyclohexylmethoxy-5-nitrosopyrimidin-2-yl)amino]propan-1-ol; IC50 =0.16 μm), while in the 5-cyano-NNO-azoxy series the most active compound was 9 b (4-amino-5-[(Z)-cyano-NNO-azoxy]-2-{[(2S)-1-hydroxypropan-2-yl]amino}-6-cyclohexylmethoxypyrimidine; IC50 =0.30 μm). Taken together, these new analogues of NU6027 enhance our understanding of the structure-activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.
Collapse
Affiliation(s)
- Daniela Cortese
- Department of Drug Science and Technology, Università degli Studi di Torino, Via P. Giuria 9, 10125, Turin, Italy
| | - Konstantin Chegaev
- Department of Drug Science and Technology, Università degli Studi di Torino, Via P. Giuria 9, 10125, Turin, Italy
| | - Stefano Guglielmo
- Department of Drug Science and Technology, Università degli Studi di Torino, Via P. Giuria 9, 10125, Turin, Italy
| | - Lan Z Wang
- Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK
| | - Bernard T Golding
- Northern Institute for Cancer Research, Bedson Building, School of Chemistry, Newcastle University, Newcastle Upon Tyne, NE1 7RU, UK
| | - Céline Cano
- Northern Institute for Cancer Research, Bedson Building, School of Chemistry, Newcastle University, Newcastle Upon Tyne, NE1 7RU, UK
| | - Roberta Fruttero
- Department of Drug Science and Technology, Università degli Studi di Torino, Via P. Giuria 9, 10125, Turin, Italy.
| |
Collapse
|
11
|
Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong AC, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR. High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors. ACS COMBINATORIAL SCIENCE 2016; 18:444-55. [PMID: 27400250 DOI: 10.1021/acscombsci.5b00155] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57 617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active compounds, whereas three series returned active hits. Structure-activity studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent potential for further development. The minimum kinase binding pharmacophore was identified, and key examples demonstrated good selectivity for ERK5 over p38α kinase.
Collapse
Affiliation(s)
- Stephanie M Myers
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Ruth H Bawn
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Louise C Bisset
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Framlington Place, Newcastle University , Paul O'Gorman Building, Newcastle upon Tyne, NE2 4HH, U.K
| | - Timothy J Blackburn
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Betty Cottyn
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Lauren Molyneux
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Ai-Ching Wong
- Cancer Research Technology, Ltd., Discovery Laboratories, Wolfson Institute for Biomedical Research, The Cruciform Building, Gower Street, London, WC1E 6BT, U.K
| | - Celine Cano
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - William Clegg
- School of Chemistry, Newcastle University , Bedson Building, Newcastle upon Tyne, NE1 7RU, U.K
| | - Ross W Harrington
- School of Chemistry, Newcastle University , Bedson Building, Newcastle upon Tyne, NE1 7RU, U.K
| | - Hing Leung
- The Beatson Institute for Cancer Research , Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, U.K
| | - Laurent Rigoreau
- Cancer Research Technology, Ltd., Discovery Laboratories, Wolfson Institute for Biomedical Research, The Cruciform Building, Gower Street, London, WC1E 6BT, U.K
| | - Sandrine Vidot
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Bernard T Golding
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Roger J Griffin
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| | - Tim Hammonds
- Cancer Research Technology, Ltd., Discovery Laboratories, Wolfson Institute for Biomedical Research, The Cruciform Building, Gower Street, London, WC1E 6BT, U.K
| | - David R Newell
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Framlington Place, Newcastle University , Paul O'Gorman Building, Newcastle upon Tyne, NE2 4HH, U.K
| | - Ian R Hardcastle
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Bedson Building, Newcastle University , Newcastle upon Tyne, NE1 7RU, U.K
| |
Collapse
|
12
|
Xu X, Yao Q. Scaffold Hopping Approach to a New Series of Pyridine Derivatives as Potent Inhibitors of CDK2. Arch Pharm (Weinheim) 2016; 349:224-31. [DOI: 10.1002/ardp.201500335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Revised: 01/14/2016] [Accepted: 01/20/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Xiaojuan Xu
- School of Chemistry and Chemical Engineering; Yancheng Teachers University; Yancheng China
| | - Qizheng Yao
- Department of Medicinal Chemistry, School of Pharmacy; China Pharmaceutical University; Nanjing China
| |
Collapse
|
13
|
One-pot synthesis and antiproliferative activity of novel 2,4-diaminopyrimidine derivatives bearing piperidine and piperazine moieties. Eur J Med Chem 2014; 84:127-34. [DOI: 10.1016/j.ejmech.2014.07.017] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 06/10/2014] [Accepted: 07/06/2014] [Indexed: 02/06/2023]
|
14
|
Trifluoroacetic Acid in 2,2,2-Trifluoroethanol Facilitates SNAr Reactions of Heterocycles with Arylamines. Chemistry 2014; 20:2311-7. [DOI: 10.1002/chem.201304336] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Indexed: 11/07/2022]
|
15
|
Boschi D, Tosco P, Chandra N, Chaurasia S, Fruttero R, Griffin R, Wang LZ, Gasco A. 6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity. Eur J Med Chem 2013; 68:333-8. [DOI: 10.1016/j.ejmech.2013.07.031] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Revised: 06/06/2013] [Accepted: 07/17/2013] [Indexed: 11/29/2022]
|
16
|
Cikotiene I, Jonusis M, Jakubkiene V. The first example of the Fischer-Hepp type rearrangement in pyrimidines. Beilstein J Org Chem 2013; 9:1819-25. [PMID: 24062848 PMCID: PMC3778328 DOI: 10.3762/bjoc.9.212] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 08/12/2013] [Indexed: 11/23/2022] Open
Abstract
A N-nitroso moiety can be used for the activation of chloropyrimidines toward a nucleophilic substitution reaction with amines. The subsequent treatment of the obtained products with aq H2SO4 can lead to either N-denitrosation to obtain 4,6-pyrimidinediamines or to a Fischer–Hepp type rearrangement to obtain 5-nitroso-4,6-pyrimidinediamines. It was found that the outcome of the reaction strongly depends on the structure of the pyrimidines. Activation of the pyrimidine ring by three groups with a positive mesomeric effect is crucial for the intramolecular nitroso group migration.
Collapse
Affiliation(s)
- Inga Cikotiene
- Department of Organic Chemistry, Faculty of Chemistry, Vilnius University, Naugarduko 24, LT-03225, Vilnius, Lithuania, Inga Cikotiene -
| | | | | |
Collapse
|
17
|
Murthy Y, Suhasini K, Pathania A, Bhushan S, Nagendra Sastry Y. Synthesis, structure activity relationship and mode of action of 3-substitutedphenyl-1-(2,2,8,8-tetramethyl-3,4,9,10-tetrahydro-2 H ,8 H -pyrano[2,3- f ]chromen-6-yl)-propenones as novel anticancer agents in human leukaemia HL-60 cells. Eur J Med Chem 2013; 62:545-55. [DOI: 10.1016/j.ejmech.2013.01.027] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Revised: 01/15/2013] [Accepted: 01/22/2013] [Indexed: 12/27/2022]
|
18
|
Ece A, Sevin F. The discovery of potential cyclin A/CDK2 inhibitors: a combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies. Med Chem Res 2013. [DOI: 10.1007/s00044-013-0571-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Lebraud H, Cano C, Carbain B, Hardcastle IR, Harrington RW, Griffin RJ, Golding BT. Trifluoroethanol solvent facilitates selective N-7 methylation of purines. Org Biomol Chem 2013; 11:1874-8. [PMID: 23381666 DOI: 10.1039/c3ob27473j] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Purines protected at N-9 by p-methoxybenzyl are methylated or ethylated in 2,2,2-trifluoroethanol at N-7 by trimethyl- or triethyl-oxonium borofluorate, respectively. Subjecting the resulting cationic species to microwave irradiation releases an N(7)-methyl- or ethyl-purine. This one-pot procedure is an efficient regiospecific method applicable to diverse substrates.
Collapse
Affiliation(s)
- Honorine Lebraud
- Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle upon Tyne, NE1 7RU, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
20
|
Jakubkienė V, Čikotienė I. Effect of substituent structure on pyrimidine electrophilic substitution: a rebuttal. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.01.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
21
|
A modular approach to trim cellular targets in anticancer drug discovery. Bioorg Med Chem Lett 2011; 21:6641-5. [DOI: 10.1016/j.bmcl.2011.09.069] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2011] [Revised: 09/18/2011] [Accepted: 09/19/2011] [Indexed: 11/20/2022]
|